Esmonova-L
Esmonova-L Products are primarily used for
Gastroesophageal reflux disease (Acid reflux), Peptic ulcer disease
About Esmonova-L Products
Uses of Esmonova-L Products
Levosulpiride+Esomeprazole is used in the treatment of gastroesophageal reflux disease (acid reflux) and peptic ulcer disease.
Esmonova-L Products side effects
Common
Side Effects of Esmonova-L are Nausea, Vomiting, Diarrhea, Headache, Flatulence, Abdominal pain, Dizziness, Joint pain, Drowsiness, Absence of menstrual periods, Breast enlargement in male, Unusual production of breast milk in women and men, Altered libido.
How Esmonova-L Products work
Levosulpiride + Esomeprazole is a combination of two medicines: Levosulpiride + Esomeprazole1 and Levosulpiride + Esomeprazole2.
Patient Concerns about Esmonova-L Products
Frequently asked questions about Esmonova-L Products
Frequently asked questions about Esmonova-L Products
Q. What are the instructions for storage and disposal of Esmonova-L Capsule SR?
Keep this medicine in the container or the pack it came in, tightly closed. Store it according to the instructions mentioned on the pack or label. Dispose of the unused medicine. Make sure it is not consumed by pets, children and other people.
Q. What is the best time to take Esmonova-L Capsule SR?
Take Esmonova-L Capsule SR exactly as directed by your doctor. It is best to take one capsule daily on an empty stomach.
Q. What are the contraindications associated with the use of Esmonova-L Capsule SR?
The use of Esmonova-L Capsule SR should be avoided in patients with known allergy to any of the components or excipients of this medicine.
Q. Can the use of Esmonova-L Capsule SR cause dizziness?
Yes, the use of Esmonova-L Capsule SR can cause dizziness (feeling faint, weak, unsteady or lightheaded) in some patients. If you feel dizzy or lightheaded, it is better to rest for some time and resume once you feel better.
Q. Does the use of Esmonova-L Capsule SR lead to increased risk of fractures?
Several studies in adults suggest that treatment with Esmonova-L Capsule SR may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist or spine. The risk of fracture was increased in patients who received high dose. High dose can mean multiple daily doses, and long-term therapy (a year or longer).